Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats.
Biochemical evaluations of the effects of the sulfhydryl-containing angiotensin-converting enzyme inhibitor (captopril) on the nephrotoxicity induced by doxorubicin in normal rats were carried out. A single dose of doxorubicin (15 mg kg-1) which caused nephrotoxicity was manifested biochemically by the elevation of serum urea after 24 and 48 h of administration. Also a severe decrease in total proteins and albumin after 4, 24 and 48 h was observed. Moreover, a decrease of non-protein sulfhydryl (-SH) concentrations in the kidney tissues after 24 h and an increase in the lipid peroxidation was observed after 4 h administration of doxorubicin. Captopril (60 mg kg-1 i.p.) injection did not induce any change in the biochemical parameters measured, however, captopril administered 1 h before doxorubicin ameliorated the biochemical toxicity induced by doxorubicin. This was evidenced by a significant reduction in serum urea and the lipid peroxidation after 4 and 24 h and a significant reduction in creatinine after 48 h. Also, the captopril amelioration was evidenced by an increase in total proteins and albumin after 4 and 24 h of doxorubicin administration. Captopril did not change non-protein sulfhydryl (-SH) concentrations or protein content in the kidney tissues. These results suggest that captopril may be beneficial as a protective agent against nephrotoxicity induced by doxorubicin.
Mansour
M A
MA
Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
El-Kashef
H A
HA
Al-Shabanah
O A
OA
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D001798:Blood Proteins / Q000378:metabolism; D002118:Calcium / Q000097:blood; D002216:Captopril / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood; D004317:Doxorubicin / Q000037:antagonists & inhibitors / Q000633:toxicity*; D005260:Female; D016166:Free Radical Scavengers; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008054:Lipid Peroxides / Q000378:metabolism; D008297:Male; D011188:Potassium / Q000097:blood; D020011:Protective Agents / Q000494:pharmacology; D051381:Rats; D012709:Serum Albumin / Q000378:metabolism; D012964:Sodium / Q000097:blood; D013438:Sulfhydryl Compounds / Q000378:metabolism; D014508:Urea / Q000097:blood
D000806:Angiotensin-Converting Enzyme Inhibitors; D000903:Antibiotics, Antineoplastic; D001798:Blood Proteins; D016166:Free Radical Scavengers; D008054:Lipid Peroxides; D020011:Protective Agents; D012709:Serum Albumin; D013438:Sulfhydryl Compounds; D004317:Doxorubicin; D014508:Urea; D002216:Captopril; D012964:Sodium; D003404:Creatinine; D011188:Potassium; D002118:Calcium